Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?

Earnings and Revenue Expectations - The specialty drugmaker is expected to post quarterly earnings of $0 83 per share, representing a year-over-year change of -6 7% [1] - Revenues are expected to be $178 98 million, down 1 3% from the year-ago quarter [1] - Empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements [1] Pacira (PCRX) Stock Performance and Estimates - The consensus EPS estimate for Pacira has been revised 0 6% lower over the last 30 days [2] - Pacira shares ended the last trading session 11 1% higher at $20 64, with a higher-than-average trading volume [3] - The stock had previously experienced a 6 2% loss over the past four weeks [3] - The sudden rise in stock price followed better-than-expected preliminary fourth-quarter 2024 sales figures and the unveiling of a five-year growth strategy [4] Industry and Peer Comparison - Pacira is a member of the Zacks Medical - Biomedical and Genetics industry [2] - Travere Therapeutics (TVTX), another stock in the same industry, finished the last trading session 4 8% lower at $18 09 but has returned 6 1% over the past month [2] - Travere's consensus EPS estimate for the upcoming report has changed -7 6% over the past month to -$0 61, representing a year-over-year change of +47 4% [5] - Travere currently holds a Zacks Rank of 2 (Buy) [5]